Core Insights - Silo Pharma, Inc. has initiated a pharmacokinetic and tolerability study for its ketamine-based injectable implant, SP-26, aimed at treating chronic pain and fibromyalgia [1][3] - The study will assess the absorption, distribution, metabolism, and excretion of the extended-release ketamine hydrochloride implants over a three-week period [2] - SP-26 is designed as a self-administered, non-opioid therapeutic that could potentially qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval [4] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including chronic pain and psychiatric disorders [5] - The company is also developing other preclinical programs targeting conditions such as PTSD, Alzheimer's disease, and multiple sclerosis [5] - Silo Pharma collaborates with universities and independent laboratories for its research and development programs [5]
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia